UK markets close in 4 hours 23 minutes
  • FTSE 100

    6,909.05
    -29.19 (-0.42%)
     
  • FTSE 250

    22,311.40
    -53.47 (-0.24%)
     
  • AIM

    1,261.11
    -2.58 (-0.20%)
     
  • GBP/EUR

    1.1515
    +0.0002 (+0.01%)
     
  • GBP/USD

    1.3885
    +0.0042 (+0.31%)
     
  • BTC-GBP

    35,586.73
    -3,660.49 (-9.33%)
     
  • CMC Crypto 200

    1,133.33
    -109.72 (-8.83%)
     
  • S&P 500

    4,134.98
    -38.44 (-0.92%)
     
  • DOW

    33,815.90
    -321.41 (-0.94%)
     
  • CRUDE OIL

    61.75
    +0.32 (+0.52%)
     
  • GOLD FUTURES

    1,788.10
    +6.10 (+0.34%)
     
  • NIKKEI 225

    29,020.63
    -167.54 (-0.57%)
     
  • HANG SENG

    29,078.75
    +323.41 (+1.12%)
     
  • DAX

    15,277.53
    -42.99 (-0.28%)
     
  • CAC 40

    6,253.19
    -14.09 (-0.22%)
     

Global Celiac Disease Epidemiology Market Forecast Report 2021: Prevalent Population in the 7 Major Markets was 6,450,607 in 2020 - Forecast to 2030

Research and Markets
·5-min read

Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Celiac Disease - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Celiac Disease (CD) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the disease, historical and forecasted Celiac Disease (CD) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Celiac Disease (CD) Detailed Epidemiology Segmentation

  • The total prevalent population of Celiac Disease in the 7 major markets was 6,450,607 in 2020 which is anticipated to increase at a CAGR of 0.53% during the study period (2018-2030).

  • The total 7MM diagnosed prevalent cases of Celiac Disease in 2020 were 1,403,779 out of which the highest diagnosed prevalent cases of this disease were in the United States, which was 701,718 which is anticipated to increase at a CAGR of 2.0% during the study period (2018-2030).

  • According to the estimates by the publisher, 252,618 and 449,099 cases of males and females were in the United States, in 2020.

  • In the United States, the number of cases of Classical, Non-classical and Sub-clinical were 189,464, 364,893 and 147,361 respectively, in 2020.

  • In the United States the maximum number of cases of Celiac Disease were in the age group of 19-39 with 256,127 cases in 2020, while the lowest number of cases were in the age group >80 with 14,034 cases in 2020.

  • In the EU5 countries the total prevalent population of Celiac Disease was maximum in Germany with 742,796 cases, followed by the United Kingdom with 660,156 cases in 2020. While, the least number of cases were in Spain, i.e., 430,359 in 2020.

  • In Japan, the prevalence of Celiac Disease was 66,130 in 2020.

Report Highlights

  • Ten Year Forecast of Celiac Disease (CD)

  • 7MM Coverage

  • Total Diagnosed Prevalent Population of Celiac Disease (CD)

  • Through several secondary sources it is quite evident that the prevalence of Celiac Disease (CD) is higher among females than in males.

  • The publisher has analyzed type-based data for Celiac Disease (CD). Celiac Disease (CD) can be of three types based on this data, namely, Classical, Non-classical and Sub-clinical Celiac Disease.

  • The report also encompasses another major segment, i.e., Age-specific Prevalent Population of Celiac Disease (CD), wherein various age groups have been considered, such as 0-18, 19-39, 49-59, 60-79 and >80. Moreover, the prevalence of Celiac Disease (CD) is maximum in the 19-39 age group.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Celiac Disease (CD)?

  • What is the historical Celiac Disease (CD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?

  • What would be the forecasted patient pool of Celiac Disease (CD) at the 7MM level?

  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Celiac Disease (CD)?

  • Out of the above-mentioned countries, which country would have the highest prevalent population of Celiac Disease (CD) during the forecast period (2021-2030)?

  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?

Reasons to Buy

  • Develop business strategies by understanding the trends shaping and driving the 7MM Celiac Disease (CD) market.

  • Quantify patient share distribution in the 7MM for Celiac Disease (CD).

  • The Celiac Disease (CD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.

  • The Celiac Disease (CD) epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the ten-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation

  • Disease Risk and Burden

  • Risk of disease by the segmentation

  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States

  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)

  • Japan

Key Topics Covered:

1 Key Insights

2 Celiac Disease Overview at a Glance

3 Executive Summary of Celiac Disease (CD)

4 Disease Background and Overview: Celiac Disease
4.1 Introduction
4.2 Types
4.2.1 Classical CD
4.2.2 Non-Classical CD
4.2.3 Silent CD
4.3 Causes
4.3.1 Genetics Factors
4.3.2 Environmental Factors
4.4 Symptoms
4.5 Pathogenesis
4.6 Pathophysiology
4.6.1 Genetics
4.6.2 Gluten, as an environmental trigger of CD
4.7 Clinical Presentation
4.8 Diagnosis
4.8.1 Diagnostic Tests of CD
4.9 Biomarkers for CD
4.9.1 Genetic Biomarkers in CD
4.9.2 Serological Biomarkers in CD
4.10 Differential diagnosis

5 Algorithm for Diagnosis of CD

6 Diagnostic Guidelines by the European Society for the Study of Coeliac Disease (ESsCD)
6.1 Recommendations on who should be tested for CD
6.2 Recommendations for Serology
6.3 Recommendations for Endoscopy and Histopathology
6.4 Recommendations for HLA-DQ2/8 Typing
6.5 Recommendations for other Diagnostic Tests
6.6 Recommendations for Diagnostic Confirmation

7 Diagnostic Guidelines by the World Gastroenterology Organization (WGO)
7.1 Recommendation for Diagnosis
7.2 Recommendations for Testing Patients
7.2.1 Patients with clinical manifestations suggestive of CD
7.2.2 Conditions associated with an increased risk for CD
7.2.3 First-degree relatives of patients with CD
7.3 Recommendations for Diagnostic Tests
7.3.1 Endoscopy in patients with suspected CD
7.3.2 Intestinal biopsy and histology
7.3.3 Serum antibody tests

8 Epidemiology and Patient Population: Key Findings
8.1 7MM Total Prevalent Population of Celiac Disease
8.2 MM Total Diagnosed Prevalent Population of Celiac Disease

9 Country Wise-Epidemiology of Celiac Disease

10 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/eby2an

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900